Brief: 89Bio Announces U.S. FDA Has Granted Breakthrough Therapy Designation For Pegozafermin In Nonalcoholic Steatohepatitis

89bio

21/09/2023 13:19

Sept 21 (Reuters) - 89Bio Inc  ETNB.O :
    * 89BIO ANNOUNCES U.S. FDA HAS GRANTED BREAKTHROUGH THERAPY
DESIGNATION FOR PEGOZAFERMIN IN NONALCOHOLIC STEATOHEPATITIS
(NASH)
    * 89BIO INC: DISCUSSIONS WITH REGULATORY AGENCIES REGARDING
NASH
PHASE 3 PROGRAM PLANNED FOR Q4 OF 2023
    * 89BIO INC: PEGOZAFERMIN WAS GENERALLY WELL-TOLERATED WITH
A
FAVORABLE SAFETY PROFILE CONSISTENT WITH PRIOR STUDIES

Source text for Eikon:  ID:nGNX9gsTfx 
Further company coverage:  ETNB.O 

 ((Reuters.Briefs@thomsonreuters.com))